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Background: Controversy exists as to the relative merits of surgical and endovascular treatment of femoropoliteal arterial
disease.
Methods: A systematic review of the literature was undertaken to identify studies comparing open surgical and percuta-
neous transluminal methods for the treatment of femoropopliteal arterial disease. Outcome data were pooled and
combined overall effect sizes were calculated using fixed or random effects models.
Results: Four randomized controlled trials and six observational studies reporting on a total of 2817 patients (1387 open,
1430 endovascular) were included. Endovascular treatment was accompanied by lower 30-day morbidity (odds ratio
[OR], 2.93; 95% confidence interval [CI], 1.34-6.41) and higher technical failure (OR, 0.10; 95% CI, 0.05-0.22) than
bypass surgery, whereas no differences in 30-day mortality between the two groups were identified (OR, 0.92; 95% CI,
0.55-1.51). Higher primary patency in the surgical treatment arm was found at 1 (OR, 2.42; 95% CI, 1.37-4.28), 2 (OR,
2.03; 95% CI, 1.20-3.45), and 3 (OR, 1.48; 95% CI, 1.12-1.97) years of intervention. Progression to amputation was
found to occur more commonly in the endovascular group at the end of the second (OR, 0.60; 95% CI, 0.42-0.86) and
third (OR, 0.55; 95% CI, 0.39-0.77) year of intervention. Higher amputation-free and overall survival rates were found
in the bypass group at 4 years (OR, 1.31; 95% CI, 1.07-1.61 and OR, 1.29; 95% CI, 1.04-1.61, respectively).
Conclusions:High-level evidence demonstrating the superiority of one method over the other is lacking. An endovascular-
first approach may be advisable in patients with significant comorbidity, whereas for fit patients with a longer-term
perspective a bypass procedure may be offered as a first-line interventional treatment. (J Vasc Surg 2013;57:242-53.)
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dLower extremity arterial disease commonly affects the
femoropopliteal segment and encompasses a range of clin-
ical manifestations associated with decrements in functional
capacity and quality of life.1 Management of the patient
with chronic lower limb ischemia involves conservative
measures, mainly consisting of atherosclerotic risk factor
modification and exercise regimens and specific interven-
tions aiming at relief of symptoms and limb salvage.2,3 In
view of the aging population and the rising prevalence of
diabetes, the global burden of severe leg ischemia is likely
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242o grow significantly, and an increasing number of revas-
ularization procedures is anticipated in the foreseeable
uture.4
Bypass surgery and endovascular interventions consti-
ute the mainstay treatment arms for femoropopliteal oc-
lusive disease. Proponents of the former emphasize the
atisfactory immediate clinical outcomes and the durability
f the method, whereas balloon angioplasty/stenting has
he advantages of being less invasive, with low procedural
orbidity and mortality in the high-surgical-risk arterio-
ath.5,6 Differing opinions as to the merits of these two
pproaches to revascularization have instigated clinical re-
earch, and several randomized controlled trials and large
ospital- and population-based surveys have been con-
ucted in an attempt to compare the clinical effectiveness of
hese treatments.7,8
The communication of knowledge, exchange of infor-
ation, and the evolution of evidence-based medicine en-
ails that both patients and physicians are expected to make
nformed decisions based on high-level evidence from ran-
omized trials and meta-analyses. The objective of the
resent article was to provide a contemporary literature
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Volume 57, Number 1 Antoniou et al 243review and perform an analysis of the outcomes of bypass
surgery and transluminal angioplasty/stenting in patients
with femoropopliteal disease potentially suitable for both
treatments. Furthermore, areas of future research are iden-
tified.
METHODS
Eligibility criteria. A prespecified protocol of the ob-
jectives and methods of the present systematic review was
established. Randomized controlled trials and observa-
tional studies comparing open surgical reconstruction and
percutaneous transluminal methods for the treatment of
femoropopliteal arterial occlusive disease were eligible for
the review. Participants of any age and gender with lower
extremity atherosclerotic arterial disease, which was con-
firmed by objective examinations, were considered. Pa-
tients were included irrespective of severity of disease or
diabetic status. Surgical reconstructions consisted of a by-
pass procedure from the common femoral or superficial
femoral artery to the above- or below-knee popliteal artery
or any infragenicular vessel. Any type of autologous or
prosthetic graft could be used. Endovascular treatment
included procedures performed transluminally, consisting
of balloon angioplasty alone or angioplasty plus bare/
covered stent placement in the diseased vessel. Outcome
was expressed by early (within 30 days) and late primary
measures. Early outcome measures included technical
failure, 30-day morbidity and mortality, and clinical
improvement. Late outcome measures comprised pri-
mary and secondary patency, progression to amputation,
amputation-free survival, and overall survival. As a sec-
ondary outcome, end point was defined the length of
Fig 1. Lithospital stay and use of hospital resources. The Society aor Vascular Surgery/American Association for Vascular
urgery reporting standards were employed to specify
isease severity at the time of presentation and define
utcome parameters.9
Information sources and search methods. An elec-
ronic search of the literature was undertaken. The search
as applied to MEDLINE (database provider PubMed,
rom 1966 to September 2011), EMBASE (database pro-
ider Ovid, from 1980 to September 2011), and Cochrane
entral Register of Controlled Trials (September 2011). A
econd-level search included a manual screen of the refer-
nce lists of selected articles identified through the elec-
ronic search. Consultation with experts in the field and
nformal inquires were obtained. No language constraints
xisted, and non-English language articles were translated.
he last search was run in September 2011. Expanded
edical subject headings and keyword searches for
stents,” “angioplasty,” “balloon dilatation,” “femoral ar-
ery,” “popliteal artery,” “vascular grafting,” “graft occlu-
ion, vascular,” “peripheral vascular diseases,” and “by-
ass,” “stent graft,” “endograft” were combined. The
iterature search protocol was verified in consultation with a
ibrarian of the University of Manchester.
Data collection and analysis. Eligibility assessment of
rials for inclusion in this review was performed indepen-
ently in an unblinded standardizedmanner by two review-
rs (G.A., G.G.). Disagreements between reviewers were
rbitrated by discussion. Furthermore, the methodological
uality of the included trials was independently assessed by
wo authors (G.A., G.G.). Each trial was evaluated for the
dequacy of allocation concealment, blind assessment of
he outcomes of interest, and performance of the analysis
re search.ccording to the intention-to-treat principle. Quality eval-
o
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ological elements, which constitute the Jadad scale and
were used to explore potential heterogeneity.10,11 The
Newcastle-Ottawa Scale was applied to assess the quality of
Table I. Study characteristics
Author (year)
No. of
patients
Study quality
(Jada/NOS) Ope
Randomized studies
Lepäntalo (2009) 44 1 Prosthetic
AK byp
Kedora (2006) 86 1 Prosthetic
AK byp
BASIL trial (2005) 452 3 Infra-ingu
BASIC trial (2004) 56 2 Femoropo
Observational studies
Scali (2011) 345 6 Femoropo
Korhonen (2011) 858 5 Femoropo
Chong (2009) 464 4 Infra-ingu
Sultan (2009) 309 5 Infra-ingu
Dosluoglu (2008) 95 7 Prosthetic
AK byp
Blair (1989) 108 5 Femoropo
bypass
AK, Above knee; ND, not defined; NOS, Newcastle-Ottawa score; NR, n
Consensus.the nonrandomized studies.12 This scale has been devel- oped to assess the quality of studies using a “star system”
maximum nine stars) in which a study is judged on three
road perspectives: the selection of the study groups, the
omparability of the groups, and the ascertainment of
cedure
Endovascular
procedure
Clinical criteria for
inclusion
ropopliteal SFA endograft Claudication or critical
ischemia
ropopliteal SFA endograft Claudication or critical
ischemia
ypass Femoropopliteal
angioplasty
Critical ischemia
al bypass Femoropopliteal
angioplasty 
stenting
Claudication
al bypass SFA angioplasty 
stenting
Claudication or critical
ischemia
al bypass Femoropopliteal
angioplasty 
stenting
Critical ischemia
ypass Femoropopliteal
angioplasty
Critical ischemia
ypass Femoropopliteal
angioplasty 
stenting
Critical ischemia
ropopliteal Femoropopliteal
angioplasty 
stenting
Claudication or critical
ischemia
al/distal Femoropopliteal
angioplasty
Critical ischemia
orted; SFA, superficial femoral artery; TASC, TransAtlantic Inter-Societyn pro
femo
ass
femo
ass
inal b
plite
plite
plite
inal b
inal b
femo
ass
plite
ot reputcome of interest.
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three trials, and refined accordingly. One review author
extracted the data from included studies (G.A.), and a
second author checked the extracted data (S.A.). Data were
identified in published material only. The collected data
were divided in three broad categories: (1) baseline clini-
cal/demographic data and technical procedure-related
characteristics, (2) primary early—within 30 days—and late
outcome data, and (3) secondary outcome data, as outlined
above.
Quantitative analyses were performed on an intention-
to-treat basis and were confined to data derived from the
period of follow-up. Patients who were assigned to a spe-
cific treatment but received no therapy or crossed over to
the alternate strategy were considered to belong to the
group randomized to the original treatment. From each
trial/study, the outcome measures were organized into a
two-by-two table to permit calculation of effect sizes for
endoluminal treatment in comparison with bypass surgery
with regard to each outcome. Patency, limb salvage, ampu-
tation-free survival, and overall survival rates were trans-
formed into a dichotomous outcome for specific time pe-
Table I. Continued.
Anatomical criteria for inclusion Primary
5-25 cm occlusion of SFA, inflow/outflow
normal, at least one run-off vessel, at
least 1 cm above/below SFA lesion
Primary patency
Stenosis/occlusion of SFA, no significant
aortoiliac disease, patent infra-popliteal
segment, at least one run-off vessel
ND
ND Time to amputatio
5-15 cm stenosis/occlusion of SFA,
absence of hemodynamically significant
aorto-iliac stenosis, at least one run-off
vessel
Re-occlusion of th
Endovascular group: no popliteal/tibial
disease  no flush SFA occlusion, open
group: NR
Primary patency
ND Overall survival, m
amputation-free
further intervent
reintervention
ND Periprocedural mo
limb salvage, lon
TASC II C/D lesions Survival free from
sustained clinica
Endovascular group: TASC-II C SFA
occlusive disease, open group: TASC-II
C/D SFA occlusive disease
Primary, assisted p
ND NDriods (eg, 12 and 24months). Data were extracted from the Eext of the article, life tables, or graphs. The reconstructed
rterial segments (bypass or angioplasty/stenting) were
onsidered to be either patent or failed requiring further
evascularization at end of each time period. Study effects
ere presented using the odds ratio (OR) in a logarithmic
cale, and the 95% confidence interval (CI) describes the
ossible range that the pooled OR could take; any CI that
ncluded 1 (the point of equal effect between the two
roups) was considered not to be statistically significant.
he OR and 95% CI for combined studies were calculated
sing the fixed-effects model of meta-analysis, unless evi-
ence of between study heterogeneity existed, in which
ase the random-effects model proposed by DerSimonian
nd Laird was used.13 For continuous variables, the stan-
ardized mean difference and corresponding 95% CI were
omputed using either the fixed or random-effects model,
ccordingly. Cochran’s Q test was applied to estimate be-
ween-study heterogeneity, and P values .05 were con-
idered significant for heterogeneity.14 For each trial, the
ffect by the inverse of its standard error was plotted.
ublication bias was assessed both visually evaluating the
ymmetry of such funnel plots, and formally using the
me measures Secondary outcome measures
Functional success, complications,
costs
ND
ath from any cause All cause mortality, 30-day morbidity/
mortality, reinterventions, health-
related quality of life, hospital
resources
oral segment Clinical improvement, primary assisted
patency, mortality, adverse events
ND
mputation,
val, freedom from
reedom from surgical
ND
/morbidity, patency,
m survival
ND
amputation,
rovement
Major adverse events, binary restenosis
rate, freedom from target lesion
revascularization, quality-adjusted
life year
y, secondary patency ND
NDoutco
n, de
e fem
ajor a
survi
ion, f
rtality
g-ter
major
l imp
rimargger’s regression intercept.15 Sensitivity analyses were
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the treatment effects were examined according to quality
and type of study. The Comprehensive Meta-Analysis soft-
ware, version 2.0 (Biostat, Englewood, NJ) was used for
the analyses.
RESULTS
Literature search results
Search of the electronic bibliographic sources identified
a total of 1221 records, and the manual search of the
references lists of the selected articles revealed no additional
relevant citations. After excluding articles whose titles or
abstracts had no relevance to the area of concern of this
systematic review, the full texts of 26 articles were retrieved
and assessed for eligibility. Four studies were excluded from
the analysis because they reported on both supra- and
infra-inguinal arterial disease, and no separate data on
femoropopliteal reconstruction could be extracted.16-19
Another three studies did not provide adequate outcome
data and were discarded.20-22 After adjusting for dupli-
cates,23-30 10 studies comparing endovascular and open
surgical reconstruction of femoropopliteal arterial disease
were identified (Fig 1).8,31-39 For studies containing dupli-
cate data, the initial report of randomized trials was used for
the purposes of the analysis, whereas longer-term outcome
data were supplemented by subsequent publications. Four
randomized controlled trials and six observational studies
entered the meta-analysis models. No unpublished relevant
studies were obtained. The literature review conformed to
Preferred Reporting Items for Systematic Reviews and
Meta-analyses statement standards.40
Study characteristics
Only one of the four randomized trials was of high
quality according to the Jadad criteria (score 3). High
concealment of allocation scores was achieved by two of the
trials, blinding was impossible in trials, including surgical or
endovascular intervention, whereas an intention-to-treat
analysis was conducted by the Bypass versus Angioplasty in
Severe Ischaemia of the Leg (BASIL) trial only. In terms of
the quality of the nonrandomized studies, high scores
according to the Newcastle-Ottawa Scale (6 stars) were
recorded in two of the six observational studies included in
the analysis (Table I).
The four randomized trials provided details on 638
patients (320 open, 318 endovascular) and another six
observational studies reported on 2179 patients (1067
open, 1112 endovascular). A total of 2817 patients consti-
tuted our final study population. The number of partici-
pants in the included studies varied between 44 and 452 in
the randomized trials, and 95 and 858 in the observational
studies. Variation in disease severity existed among the
studies, with one study including patients with claudication
only, five studies comprising patients with critical ischemia
only, and another four studies reporting on patients with
either claudication or critical ischemia (Table I). Out of the
total study population, 2080 participants (74%) received treatment for critical limb ischemia. The type of surgical
econstruction varied among the studies, including an
bove-/below-knee femoropopliteal bypass or a bypass
rom the femoral artery to an infragenicular crural vessel.
ither autologous vein or prosthetic graft was used for
hese bypasses, with most authors converging on the use
f vein graft material for a below-the-knee bypass proce-
ure whenever possible. Additionally, differences in the
ype of endoluminal intervention existed; some studies
ompared surgical infrainguinal arterial reconstruction
ith percutaneous transluminal angioplasty of the fem-
ropopliteal segment, while others compared the out-
omes of a bypass procedure with those of angioplasty
upplemented by bare or covered stent placement. The
linical and anatomical criteria for patient inclusion, as
ell as the primary and secondary outcome measures set
y the selected studies are outlined in Table I. Baseline
emographic and clinical information of the study pop-
lations are presented in Table II.
ynthesis of results and outcome
Thirty-day morbidity. Eight studies reported 30-day
orbidity rates. The incidence of 30-day morbidity was 33%
n the surgical intervention arm and 17% in the endovascular
ntervention arm (OR, 2.93; 95% CI, 1.34-6.41; P  .007).
vidence of heterogeneity was found among these studies (Q
alue, 29.199; df [Q], 7; P  .001), whereas there was no
vidence of publication bias (P  .367). The incidence of
0-day morbidity in the randomized trials was 39% in the
pen group and 32% in the endovascular group (OR, 1.36;
5%CI, 0.97-1.92;P .079).No evidence of heterogeneity
xisted among the trials (Q value, 2.852; df [Q], 3; P 
415), and the likelihood for publication bias was low (P
955; Fig 2).
Thirty-day mortality. The 30-day mortality rate was
% in the bypass group and 3% in the endovascular group
OR, 0.92; 95% CI, 0.55-1.51; P  .720). No significant
eterogeneity among the studies was identified (Q value,
.195; df [Q], 5; P  .146), and there was no evidence of
ublication bias (P  .625). Of the randomized trials,
0-day mortality was recorded in the BASIL trial only,
hich revealed no significant difference between the study
roups (P  .359).
Technical failure. Technical failure rates were re-
orted by all randomized trials and four of the observa-
ional studies. Technical failure occurred in 1% of the
atients in the bypass group and 9% of the patients in the
ndovascular group (OR, 0.10; 95% CI, 0.05-0.22; P 
001). No significant heterogeneity was demonstrated
mong the studies (Q value, 3.277; df [Q], 5; P  .657)
nd publication bias was low (P  .751). The technical
ailure rate in the randomized trials was 1.5% and 14.6% in
he open and endovascular group, respectively (OR, 0.11;
5% CI, 0.04-0.25; P  .001). No heterogeneity was
ound (Q value, 0.290; df [Q], 2; P  .865), and publica-
ion bias was low (P  .108; Fig 3).
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ment, as defined by the reporting standards document,
were provided by two randomized trials only. Clinical
improvement was noticed in 83% of the patients in the
bypass group and in 79% of the patients in the endovascular
group (OR, 1.51; 95% CI, 0.55-4.15; P  .430). Co-
chran’sQ test revealed low levels of heterogeneity (Q value,
3.622; df [Q], 1; P  .057).
Primary patency. Primary patency rates at 1 year were
Table II. Demographic and clinical characteristics of the s
Author (year) Lepäntalo (2009) Kedora (20
Group (No. of
patients)
Open
(n  21)
Endovascular
(n  23)
Open
(n  46)
End
(n
Mean age
(range or SD)
66 (53-80) 64 (48-79) 67 (40-86) 72
Male gender 12 (57%) 13 (57%) 36 (78%) 32
Hypertension 12 (57%) 15 (65%) 42 (91%) 30
Diabetes
mellitus
3 (14%) 8 (35%) 20 (43%) 14
Coronary artery
disease
6 (29%) 4 (17%) 22 (48%) 13
Dyslipidemia 9 (43%) 16 (70%) 21 (46%) 23
Cerebrovascular
disease
2 (10%) 2 (9%) NR
Smoking 15 (71%) 16 (70%) 27 (59%) 22
Critical ischemia 2 (10%) 3 (13%) 19 (41%) 9
Mean ankle-
brachial
pressure index
(range or SD)
0.61
(0.49-0.76)
0.62
(0.33-0.92)
NR
Scali (2011) Korhonen (2011)
Open
(n  141)
Endovascular
(n  204)
Open
(n  341)
Endovascular
(n  517)
66 (22) 70 (11) 72 (10) 75 (11)
101 (72%) 129 (63%) 168 (49%) 316 (61%)
115 (82%) 192 (94%) 237 (70%) 394 (76%)
64 (45%) 105 (51%) 137 (40%) 301 (58%)
53 (38%) 110 (54%) 207 (61%) 318 (62%)
105 (74%) 160 (78%) NR NR
NR NR 45 (13%) 110 (21%)
75 (53%) 70 (34%) 127 (37%) 122 (24%)
82 (58%) 103 (50%) 341 (100%) 517 (100%)
NR NR NR NR
Dosluoglu (2008)
Open (n  46) Endovascular (n  49)
65 (8) 72 (10)
NR NR
34 (74%) 38 (78%)
24 (52%) 33 (67%)
29 (63%) 32 (65%)
29 (63%) 34 (69%)
5 (11%) 9 (18%)
31 (67%) 18 (37%)
20 (43%) 39 (80%)
0.46 (0.19) 0.54 (0.21)
NR, Not reported; SD, standard deviation.
aMedian value.recorded in three randomized trials and four observational 1tudies. Primary patency at 1 year was achieved in 72% of
he bypass limbs and 62% of the limbs that had endoluminal
rocedures (OR, 2.42; 95% CI, 1.37-4.28; P  .002).
vidence of significant heterogeneity among the studies
xisted (Q value, 20.006; df [Q], 6; P  .003), and the
ikelihood of publication bias was insignificant (P 
275). Primary patency results at 1 year in favor of the
pen surgical reconstruction were sustained after meta-
nalyzing the randomized trials only (OR, 3.54; 95% CI,
populations
BASIL trial (2005) BASIC trial (2004)
ular
)
Open
(n  228)
Endovascular
(n  224)
Open
(n  25)
Endovascular
(n  31)
4) NR NR 66 (42-83)a 68 (45-84)a
) 141 (62%) 128 (57%) 16 (64%) 21 (70%)
) 134 (59%) 141 (63%) 8 (32%) 17 (55%)
) 95 (42%) 95 (42%) 3 (12%) 5 (16%)
) 76 (33%) 86 (38%) 4 (16%) 7 (23%)
) NR NR 6 (24%) 8 (26%)
57 (25%) 40 (18%) 4 (16%) 3 (10%)
) 187 (82%) 176 (79%) 15 (60%) 12 (39%)
) 228 (100%) 224 (100%) 0 (0%) 10 (0%)
NR NR 0.58
(0.22-0.92)a
0.55
(0.15-0.84)a
Chong (2009) Sultan (2009)
Open
n  364)
Endovascular
(n  100)
Open
(n  119)
Endovascular
(n  190)
74a 77a 70 (14) 73 (13)
3 (45%) 47 (47%) 77 (65%) 86 (45%)
8 (71%) 88 (88%) NR NR
0 (66%) 75 (75%) 25 (21%) 44 (23%)
0 (44%) 48 (48%) 53 (45%) 91 (48%)
NR NR NR NR
6 (21%) 28 (28%) NR NR
6 (62%) 70 (70%) 40 (34%) 67 (35%)
4 (100%) 100 (100%) 119 (100%) 190 (100%)
0 (0-1.01)a 0.45 (0-1.43)a NR NR
Blair (1989)
Open (n  56) Endovascular (n  52)
68 73
30 (54%) 21 (40%)
38 (68%) 35 (67%)
37 (66%) 29 (56%)
NR NR
NR NR
32 (57%) 30 (58%)
27 (48%) 18 (35%)
56 (100%) 52 (100%)
0.38 (0.14) 0.40 (0.18)tudy
06)
ovasc
 40
(40-8
(80%
(75%
(35%
(33%
(58%
NR
(55%
(23%
NR
(
16
25
24
16
7
22
36
0.4.00-12.54; P  .050); meta-analysis of those trials
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[Q], 2; P  .036), and no significant evidence of publi-
cation bias (P  .192). Similarly to the primary patency
rates at 1 year, meta-analysis of the whole study popula-
tion revealed higher primary patency rates at 2 and 3
years in the open group (Table III); however, such a
favorable outcome for the open surgical intervention
arm did not exist after conducting sensitivity analysis,
including the randomized trials only (Table IV). Four-
year primary patency rates were provided by two obser-
vational studies only, meta-analysis of which found no
significant differences between the two groups (OR,
1.09; 95% CI, 0.74-1.60; P  .662).
Progression to amputation. Progression to limb loss
within 1 year of intervention occurred in 12% of the pa-
tients in the surgical intervention arm and 11% of the
patients in the percutaneous intervention arm (OR, 1.16;
95% CI, 0.40-3.33; P  .788). Significant heterogeneity
was identified among the studies (Q value, 20.851; df [Q],
4; P.001), and the possibility of publication bias was low
(P  .469). Similarly, meta-analysis of the randomized
Fig 2. Differences in 30-day morbidity between the op
study population (a) and the randomized trials (b). A, E
confidence interval.trials showed no significant difference in the limb loss rate 9ithin 1 year of intervention (OR, 2.41; 95% CI, 0.39-
4.74; P  .342). Limb loss rates within 2 and 3 years of
ntervention was found to be higher in the endovascular
roup on meta-analysis of the whole study population
Table III), whereas meta-analysis of the randomized trials
nly did not confirm those results (Table IV). At the end of
he fourth year, the benefit in limb salvage in favor of the
ypass group was eliminated, with no significant differences
etween the two groups (Table III).
Amputation-free survival. The amputation-free sur-
ival rate within 1 year of intervention was 76% in the open
roup and 71% in the endovascular group (OR, 1.29; 95%
I, 0.86-1.93; P  .214). Significant evidence of hetero-
eneity among the studies existed (Q value, 9.031; df [Q],
; P .029), whereas the likelihood of publication bias was
ow (P .905). The amputation-free survival was found to
e statistically insignificant between the groups within 2
nd 3 years of intervention (Table III); however, a benefit
f bypass surgery over endoluminal intervention in terms of
he 4-year amputation-free survival was found (OR, 1.31;
rgical and endovascular intervention arms in the whole
ascular intervention; B, open surgical intervention; CI,en su
ndov5% CI, 1.07-1.61; P  .009).
JOURNAL OF VASCULAR SURGERY
Volume 57, Number 1 Antoniou et al 249Fig 3. Differences in technical failure between the open surgical and endovascular intervention arms in the whole study
population (a) and the randomized trials (b).A,Endovascular intervention;B,open surgical intervention;CI, confidence interval.Table III. Summary meta-analysis outcomes in the whole study population
Outcome measure Meta-analysis model OR (95% CI) P value P value for publication bias
Thirty-day morbidity Random effects 2.93 (1.34-6.41) .007 .367
Thirty-day mortality Fixed effects 0.92 (0.55-1.51) .720 .625
Technical failure Fixed effects 0.10 (0.05-0.22) .001 .751
Clinical improvement Fixed effects 1.51 (0.55-4.15) .430 —
Hospital stay Fixed effects — .001 —
Primary patency
1 year Random effects 2.42 (1.37-4.28) .002 .275
2 years Random effects 2.03 (1.20-3.45) .009 .691
3 years Fixed effects 1.48 (1.12-1.97) .006 .476
4 years Fixed effects 1.09 (0.74-1.60) .662 —
Limb loss
1 year Random effects 1.16 (0.40-3.33) .788 .469
2 years Fixed effects 0.60 (0.42-0.86) .005 .128
3 years Fixed effects 0.55 (0.39-0.77) .001 .054
4 years Random effects 1.23 (0.07-22.00) .875 —
Amputation-free survival
1 year Random effects 1.29 (0.86-1.93) .214 .905
2 years Random effects 1.10 (0.73-1.66) .653 .324
3 years Fixed effects 1.20 (0.99-1.45) .067 .053
4 years Fixed effects 1.31 (1.07-1.61) .009 .382
Overall survival
1 year Fixed effects 1.17 (0.91-1.49) .222 .680
2 years Fixed effects 1.22 (0.97-1.53) .086 .417
3 years Random effects 1.88 (0.65-5.46) .245 .787
4 years Fixed effects 1.29 (1.04-1.61) .020 .999CI, Confidence interval; OR, odds ratio.
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vention, 82% of the patients in the surgical intervention arm
were alive, and the overall survival rate in the endoluminal
intervention arm was 79% (OR, 1.17; 95% CI, 0.91-1.49;
P  .222). No significant heterogeneity among the study
was revealed (Q value, 4.898; df [Q], 3; P .179), and the
possibility of publication bias was low (P .680). Similarly,
no significant differences between the two groups were
found on the meta-analysis of the randomized trials (OR,
0.78; 95% CI, 0.49-1.23; P  .281). The overall survival
within 2, 3, and 4 years of intervention was not significant
between the two groups, either (Tables III and IV).
Hospital stay. Two observational studies only re-
ported the mean duration of hospital stay and the standard
deviations (SDs). Pooled analysis of these studies revealed
that endovascular treatment was associated with short hos-
pital stay as compared with open surgical revascularization
(standardized mean difference, 0.56; 95% CI, 0.36-0.76;
P  .001). There was no evidence of heterogeneity be-
tween the studies (Q value, 0.306; df [Q], 1; P  .580).
DISCUSSION
Endovascular technology has revolutionized the treat-
ment of lower extremity arterial disease over the last de-
cades.41,42 The significant cardiovascular comorbid burden
accompanying the patient with lower limb ischemia has
emphasized the need for minimally invasive therapeutic
methods, combining low interventional risks with satisfac-
tory late outcomes. Increasingly, conventional operative
Table IV. Summary meta-analysis outcomes in randomize
Outcome measure
Meta-analysis
model
30-day morbidity Fixed effects
30-day mortality —
Technical failure Fixed effects
Clinical improvement Fixed effects
Hospital stay —
Primary patency
1 year Random effects
2 years Fixed effects
3 years Fixed effects
4 years —
Limb loss
1 year Fixed effects
2 years Fixed effects
3 years Fixed effects
4 years —
Amputation-free survival
1 year —
2 years —
3 years —
4 years —
Overall survival
1 year Fixed effects
2 years Fixed effects
3 years Fixed effects
4 years Fixed effects
CI, Confidence interval; OR, odds ratio.strategies are being substituted with less invasive percuta- ceous techniques with reported clinical efficacy and clear
eri-procedural morbidity and mortality benefits.3,43 De-
pite these perceived advantages, late clinical failure second-
ry to restenosis or arterial occlusion remains a limitation of
ercutaneous catheter-based interventions.44 Bypass sur-
ery has proven clinical efficacy and long-term outcomes, as
xpressed by patency rates, particularly in complex femoro-
opliteal disease.3,5 The present review was conducted to
nvestigate the existing evidence on the therapeutic appli-
ations for femoropopliteal arterial occlusive disease and
rovide evidence-based answers to the intriguing contro-
ersy as to which is the optimal first-line treatment of such
atients. Meta-analysis of published studies found that,
ven though there was an early postprocedural outcome
enefit in favor of endovascular treatment, the short- and
edium-term results were broadly similar with respect to
atency, limb salvage, amputation-free survival, and overall
urvival rates.
Early outcome in most of the studies was expressed by
he 30-day morbidity and mortality figures and technical
uccess rates. Meta-analysis of the whole study population
evealed that endoluminal treatments were accompanied
ith less peri-interventional and 30-day morbidity com-
ared with bypass surgery (P  .007). This outcome dif-
erence was less pronounced when sensitivity analyses, in-
luding the randomized trials only, were performed (P 
079). However, when interpreting this parameter, it
hould be taken into account that a number of patients with
ailed angioplasty subsequently underwent surgical revas-
ntrolled trials
R (95% CI) P value
P value for
publication bias
6 (0.97-1.92) .079 .955
— — —
1 (0.04-0.25) .001 .108
1 (0.55-4.15 .430 —
— — —
4 (1.00-12.54) .050 .192
5 (0.93-2.94) .089 .212
9 (0.61-2.34) .610 —
— — —
1 (0.39-14.74) .342 —
2 (0.54-12.76) .233 .493
2 (0.77-28.96) .094 —
— — —
— — —
— — —
— — —
— — —
8 (0.49-1.23) .281 —
5 (0.57-1.27) .424 —
7 (0.67-1.42) .884 —
3 (0.87-1.75) .247 —d co
O
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Volume 57, Number 1 Antoniou et al 251perioperative morbidity data of whom were involved in the
intention-to-treat analysis. The 30-day mortality was simi-
lar in the two treatment arms and was noticed to be low
despite the considerable comorbidity of the patients of the
study cohorts. Technical failure was found to be signifi-
cantly higher in the endoluminal group (P  .001). This
figure should be cautiously evaluated and interpreted, be-
cause of the fact that most authors did not define technical
success according to specific uniform criteria and standards.
In terms of the late outcomes, authors of the included
studies used one or more of the parameters outlined in
Tables III and IV to assess the durability and late effects of
infra-inguinal revascularization. Analysis of the outcome
effects at specific time points demonstrated a trend towards
a higher primary patency of the reconstructed femoropop-
liteal segment in the bypass group within the first and
second year of intervention. In the longer term, however,
this patency benefit of the open group seemed to be elim-
inated, with both treatment arms demonstrating similar
patency figures at 4-year follow-up. Progression to ampu-
tation was found to occur more commonly in the endovas-
cular group at the end of the second and third year of
intervention, whereas meta-analysis of the randomized tri-
als only did not reproduce this finding. Both amputation-
free and overall survival were not significantly different in
the examined groups within the first 3 years of intervention,
whereas longer-term analysis revealed a trend towards a
better outcome in the bypass group. This finding is consis-
tent with that of the largest randomized trial (BASIL trial),
which concluded that for patients surviving for at least 2
years after randomization, a bypass-first strategy was asso-
ciated with improved overall and amputation-free sur-
vival.27,33
Based on the aforementioned results, an endovascular-
first approach may be advisable in patients with significant
comorbidity, who have a relatively short life expectancy.
Despite the higher immediate failure rate, morbidity asso-
ciated with angioplasty is low, the hospital stay is short, and
subsequent surgical intervention is not prejudiced should it
be necessary. For fit patients, however, in whom a longer-
term perspective is anticipated, a bypass procedure, which
seems to provide a more durable benefit, may be offered as
a first-line treatment. Other parameters, such as the type of
the bypass conduit available (prosthetic or vein) and the
need for above- or below-knee intervention, should be
considered before a decision for open versus endovascular
intervention as a first-line therapy for fit patients is made.
Before clear implications for clinical practice can be
drawn, it must be remembered that the trials and studies
included in the analysis represent a subset of patients suf-
fering from chronic lower limb ischemia. Extrapolation to
the entire population of patients with this disorder is re-
stricted by the fact that several patients presenting to vas-
cular units may have an extremely poor prognosis or
significant comorbidities and, therefore, be regarded as
unsuitable or unfit for revascularization or even do not
undergo any diagnostic imaging at all. Furthermore, a large
proportion of patients with lower extremity arterial disease (ave multilevel patterns of disease and cannot be involved
n such comparative studies, as they are suitable for major
rterial reconstructive surgery, endoluminal procedures in
everal arterial segments, or hybrid open and endovascular
evascularization.45 The studies included in the analysis do
ot focus on the same population, as the severity of lower
xtremity arterial disease varies significantly (patients with
laudication vs patients with critical ischemia). Treatment
f femoropopliteal disease for claudicants, in whom it may
e the only disease burden, is different from treating the
ame disease level in patients with critical limb ischemia,
here a multilevel inflow/outflow pattern of disease is
ikely to exist. Combining these groups into one makes the
nterpretation of the results hazardous, because of the fact
hat the outcomes are so disparate.
The results of the present analysis should also be inter-
reted with caution because of the existing heterogeneity
mong the study populations included. Severity of disease
aried considerably among the studies, with some authors
aving included patients with critical ischemia or claudica-
ion only, and some others having intervened upon mixed
isease severity groups. Moreover, open revascularization
onsisted of prosthetic or vein, above- or below-knee by-
ass, whereas a minority of patients underwent common
emoral endarterectomy.33 Similarly, percutaneous translu-
inal angioplasty ranged from simple balloon dilatation to
are stent or stent graft placement in the diseased femoro-
opliteal segment, whereas a small number of patients had
ndoluminal reconstruction of the infra-genicular popliteal
rtery or tibial vessels only.37 The presence of variability in
he therapeutic methods among the studies makes it diffi-
ult to reach solid conclusions regarding the superiority of
ither treatment. Furthermore, anatomical classification of
nfrainguinal disease was either not defined or inconsis-
ently reported by participating studies. The four trials and
ix observational studies each evaluate different end points,
uch as amputation-free survival, perioperative and long-
erm mortality, and patency time points. Therefore, trying
o combine these data statistically makes it difficult to
spouse the statistical validity of this practice to make a
ore grand recommendation for clinical practice.
Both randomized and nonrandomized study data have
everal limitations to which attention should be drawn. Of
he four randomized trials, none of them really reflects the
tate of the art; the BASIL and Bypass or Angioplasty in
evere Intermittent Claudication (BASIC) trials involved
alloon angioplasty only, whereas there is now a series of
ublished studies indicating that bare nitinol stents give
uperior results.46 The BASIC is not a very good study for
ther reasons, too; it took many centers many years to
ecruit a small number of cases; therefore, it is almost
ertainly not a representative sample. Numerically, the ran-
omized trials are dominated by the BASIL trial. Some of
he nonrandomized studies (eg, Scali et al) make no at-
empt at matching patients for disease severity.35 The dis-
repancy between the pooled clinical outcomes of the
hole study population and those of the randomized trials
30-day morbidity, primary patency, and limb loss) points
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pare similar patient populations and may introduce bias to
the analysis.
Evolving surgical and endovascular strategies embrace
new technologies in an attempt to improve the safety and
efficacy of revascularization procedures for lower extremity
arterial occlusive disease. Drug-eluting stents and drug-
coated balloons, and the use of heparin-bonded expanded
polytetrafluoroethylene grafts and stent grafts are currently
being evaluated in the primary treatment of femoropopli-
teal segment disease for selected patients.41 Research on
polymer-based and alloy-based bioabsorbable stents is a
promising field, which, if substantiated, may change endo-
vascular treatment paradigms. Such novel treatments along
with the imperative understanding of medical treatment
focused on the individual patient’s needs and expectations
may constitute areas of future research.
CONCLUSIONS
There is insufficient evidence to demonstrate the supe-
riority of one method over the other. Existing randomized
trials and observational studies are limited by the variability
in disease severity and methods of treatment. An endovas-
cular-first approach may be advisable in patients with sig-
nificant comorbidity, whereas for fit patients with a longer-
term perspective, a bypass procedure may be offered as a
first-line interventional treatment. Further randomized
controlled trials evaluating the outcomes of surgical and
endovascular treatment in carefully selected patients are
required to delineate the efficacy of these methods for the
treatment of femoropopliteal arterial disease.
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